Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 36Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Pancreatic Neoplasms 4Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Advanced Breast Cancer 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Inflammation 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombosis 1Thromboembolism 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Primary Myelofibrosis 1Oligodendroglioma 1Neoplasms, Neuroepithelial 1Myeloproliferative Disorders 1

Interventions

palbociclib 1defactinib 1adavosertib 1Taxes 1Radiation 1RO5126766 1Platinum 1Paclitaxel 1Fulvestrant 1Dasatinib 1Congresses as Topic 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Endometrioid × palbociclib × Clear all
NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡